BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

16 related articles for article (PubMed ID: 38716219)

  • 1. Botensilimab plus balstilimab in relapsed/refractory microsatellite stable metastatic colorectal cancer: a phase 1 trial.
    Bullock AJ; Schlechter BL; Fakih MG; Tsimberidou AM; Grossman JE; Gordon MS; Wilky BA; Pimentel A; Mahadevan D; Balmanoukian AS; Sanborn RE; Schwartz GK; Abou-Alfa GK; Segal NH; Bockorny B; Moser JC; Sharma S; Patel JM; Wu W; Chand D; Rosenthal K; Mednick G; Delepine C; Curiel TJ; Stebbing J; Lenz HJ; O'Day SJ; El-Khoueiry AB
    Nat Med; 2024 Jun; ():. PubMed ID: 38871975
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dopamine pre-treatment impairs the anti-cancer effect of integrated stress response- and TRAIL pathway-inducing ONC201, ONC206 and ONC212 imipridones in pancreatic, colorectal cancer but not DMG cells.
    Zhang Y; Tapinos N; Lulla R; El-Deiry WS
    Am J Cancer Res; 2024; 14(5):2453-2464. PubMed ID: 38859853
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nivolumab plus low-dose ipilimumab in previously treated patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from CheckMate 142.
    André T; Lonardi S; Wong KYM; Lenz HJ; Gelsomino F; Aglietta M; Morse MA; Van Cutsem E; McDermott R; Hill A; Sawyer MB; Hendlisz A; Neyns B; Abdullaev S; Memaj A; Lei M; Dixon M; Kopetz S; Overman MJ
    Ann Oncol; 2022 Oct; 33(10):1052-1060. PubMed ID: 35764271
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): a multicentre, open-label, randomised, controlled, phase 2 trial.
    Antoniotti C; Rossini D; Pietrantonio F; Catteau A; Salvatore L; Lonardi S; Boquet I; Tamberi S; Marmorino F; Moretto R; Ambrosini M; Tamburini E; Tortora G; Passardi A; Bergamo F; Kassambara A; Sbarrato T; Morano F; Ritorto G; Borelli B; Boccaccino A; Conca V; Giordano M; Ugolini C; Fieschi J; Papadopulos A; Massoué C; Aprile G; Antonuzzo L; Gelsomino F; Martinelli E; Pella N; Masi G; Fontanini G; Boni L; Galon J; Cremolini C;
    Lancet Oncol; 2022 Jul; 23(7):876-887. PubMed ID: 35636444
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanisms of Immunosuppression in Colorectal Cancer.
    Zhang Y; Rajput A; Jin N; Wang J
    Cancers (Basel); 2020 Dec; 12(12):. PubMed ID: 33419310
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer.
    André T; Shiu KK; Kim TW; Jensen BV; Jensen LH; Punt C; Smith D; Garcia-Carbonero R; Benavides M; Gibbs P; de la Fouchardiere C; Rivera F; Elez E; Bendell J; Le DT; Yoshino T; Van Cutsem E; Yang P; Farooqui MZH; Marinello P; Diaz LA;
    N Engl J Med; 2020 Dec; 383(23):2207-2218. PubMed ID: 33264544
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dose intensification of TRAIL-inducing ONC201 inhibits metastasis and promotes intratumoral NK cell recruitment.
    Wagner J; Kline CL; Zhou L; Campbell KS; MacFarlane AW; Olszanski AJ; Cai KQ; Hensley HH; Ross EA; Ralff MD; Zloza A; Chesson CB; Newman JH; Kaufman H; Bertino J; Stein M; El-Deiry WS
    J Clin Invest; 2018 Jun; 128(6):2325-2338. PubMed ID: 29533922
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study.
    Overman MJ; McDermott R; Leach JL; Lonardi S; Lenz HJ; Morse MA; Desai J; Hill A; Axelson M; Moss RA; Goldberg MV; Cao ZA; Ledeine JM; Maglinte GA; Kopetz S; André T
    Lancet Oncol; 2017 Sep; 18(9):1182-1191. PubMed ID: 28734759
    [TBL] [Abstract][Full Text] [Related]  

  • 9. First-in-Human Clinical Trial of Oral ONC201 in Patients with Refractory Solid Tumors.
    Stein MN; Bertino JR; Kaufman HL; Mayer T; Moss R; Silk A; Chan N; Malhotra J; Rodriguez L; Aisner J; Aiken RD; Haffty BG; DiPaola RS; Saunders T; Zloza A; Damare S; Beckett Y; Yu B; Najmi S; Gabel C; Dickerson S; Zheng L; El-Deiry WS; Allen JE; Stogniew M; Oster W; Mehnert JM
    Clin Cancer Res; 2017 Aug; 23(15):4163-4169. PubMed ID: 28331050
    [No Abstract]   [Full Text] [Related]  

  • 10. First-In-Class Small Molecule ONC201 Induces DR5 and Cell Death in Tumor but Not Normal Cells to Provide a Wide Therapeutic Index as an Anti-Cancer Agent.
    Allen JE; Crowder RN; El-Deiry WS
    PLoS One; 2015; 10(11):e0143082. PubMed ID: 26580220
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dual inactivation of Akt and ERK by TIC10 signals Foxo3a nuclear translocation, TRAIL gene induction, and potent antitumor effects.
    Allen JE; Krigsfeld G; Mayes PA; Patel L; Dicker DT; Patel AS; Dolloff NG; Messaris E; Scata KA; Wang W; Zhou JY; Wu GS; El-Deiry WS
    Sci Transl Med; 2013 Feb; 5(171):171ra17. PubMed ID: 23390247
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).
    Eisenhauer EA; Therasse P; Bogaerts J; Schwartz LH; Sargent D; Ford R; Dancey J; Arbuck S; Gwyther S; Mooney M; Rubinstein L; Shankar L; Dodd L; Kaplan R; Lacombe D; Verweij J
    Eur J Cancer; 2009 Jan; 45(2):228-47. PubMed ID: 19097774
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nivolumab plus ONC201 plus in microsatellite stable (MSS) metastatic colorectal cancer (mCRC) patients: a Brown University Oncology Research Group phase Ib/II study (BrUOG379).
    Almhanna K; Breakstone R; Raufi A; Wood R; Webber A; Dionson S; Cavanagh L; Seyhan AA; Safran H; El-Deiry W
    Transl Gastroenterol Hepatol; 2024; 9():15. PubMed ID: 38716219
    [TBL] [Abstract][Full Text] [Related]  

  • 14.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 1.